Tim Walbert currently serves as Managing Partner of HRZN Partners LLC and a Senior Advisor to Amgen and Senior Advisor to Patient Square Capital. Most recently, he was Chairman, President, and Chief Executive Officer of Horizon Therapeutics, which he grew to approximately $4 billion in annual sales prior to its $28.3 billion acquisition by Amgen in 2023; earlier, he led IDM Pharma Inc. through its acquisition by Takeda and held senior roles at Abbott (now AbbVie), where he led the global launch of HUMIRA(r), as well as at G.D. Searle & Company, Merck & Co. and Wyeth.

Mr. Walbert currently serves on the boards of several public and private companies, including BioMarin Pharmaceutical, Mirum Pharmaceuticals, Kardigan, Inc, Odyssey Therapeutics, Catalent, Crystalys Therapeutics (Chairman) and Apollo Therapeutics (Chairman). His prior board experience includes Aurinia Pharmaceuticals, Exicure (Chairman), Assertio (Chairman), Raptor Pharmaceutical Corp., Century Therapeutics, Sagimet Biosciences, Cour Therapeutics, XOMA Corporation and Sucampo Pharmaceuticals.

Mr. Walbert holds a B.A. from Muhlenberg College.